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ORIGINAL ARTICLE
Disruption of SF3B1 results in deregulated expression and
splicing of key genes and pathways in myelodysplastic
syndrome hematopoietic stem and progenitor cells
H Dolatshad1,12, A Pellagatti1,12, M Fernandez-Mercado1, BH Yip1, L Malcovati2,3, M Attwood1, B Przychodzen4, N Sahgal5, AA Kanapin6,
H Lockstone5, L Scifo1, P Vandenberghe7, E Papaemmanuil8, CWJ Smith9, PJ Campbell8, S Ogawa10, JP Maciejewski4, M Cazzola2,3,
KI Savage11 and J Boultwood1
The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplastic syndrome (MDS), particularly in patients with
refractory anemia with ring sideroblasts (RARS). We investigated the functional effects of SF3B1 disruption in myeloid cell lines:
SF3B1 knockdown resulted in growth inhibition, cell cycle arrest and impaired erythroid differentiation and deregulation of many
genes and pathways, including cell cycle regulation and RNA processing. MDS is a disorder of the hematopoietic stem cell and we
thus studied the transcriptome of CD34+ cells from MDS patients with SF3B1 mutations using RNA sequencing. Genes signiﬁcantly
differentially expressed at the transcript and/or exon level in SF3B1 mutant compared with wild-type cases include genes that are
involved in MDS pathogenesis (ASXL1 and CBL), iron homeostasis and mitochondrial metabolism (ALAS2, ABCB7 and SLC25A37) and
RNA splicing/processing (PRPF8 and HNRNPD). Many genes regulated by a DNA damage-induced BRCA1–BCLAF1–SF3B1 protein
complex showed differential expression/splicing in SF3B1 mutant cases. This is the ﬁrst study to determine the target genes of
SF3B1 mutation in MDS CD34+ cells. Our data indicate that SF3B1 has a critical role in MDS by affecting the expression and splicing
of genes involved in speciﬁc cellular processes/pathways, many of which are relevant to the known RARS pathophysiology,
suggesting a causal link.
Leukemia (2015) 29, 1092–1103; doi:10.1038/leu.2014.331
INTRODUCTION
The myelodysplastic syndromes (MDS) are a heterogeneous group
of clonal hematopoietic stem cell (HSC) malignancies character-
ized by blood cell dysplasia and peripheral blood cytopenia.
Approximately 30–40% of MDS patients will develop acute
myeloid leukemia (AML).1
The recent discovery of somatic splicesomal mutations in MDS
has revealed a new leukemogenic pathway involving spliceosomal
dysfunction.2,3 Somatic mutations in the splicing factor genes
SF3B1, U2AF1, SRSF2 and ZRSR2 are frequent in MDS patients.4
Importantly, these genes encode proteins that are all involved in
3′-splice site recognition during pre-messenger RNA (pre-mRNA)
processing. Splicing factor gene mutations occur in over 50% of
MDS patients, are highly speciﬁc to this disorder, and occur in a
mutually exclusive manner.5–7
SF3B1, encoding a core component of the U2 small nuclear
ribonucleoprotein, involved in the recognition of the branchpoint
sequence, is the most commonly mutated gene found in MDS
(20–28% of all patients).2,8,9 We and others have shown that
mutations of the splicing factor SF3B1 are found in a high
percentage (470%) of MDS patients whose disease is
characterised by the presence of ring sideroblasts, including both
refractory anemia with ring sideroblasts (RARS) and refractory
cytopenia with multilineage dysplasia and ring sideroblasts
(RCMD-RS).2,8 The close association between SF3B1 mutation and
the presence of ring sideroblasts is consistent with a causal
relationship and makes this the ﬁrst gene to be strongly
associated with a speciﬁc morphological feature of MDS. Ring
sideroblasts are characterised by an excess accumulation of iron in
the mitochondria of erythroblasts,10 and SF3B1 mutant RARS cases
show altered iron distribution characterised by coarse iron
deposits compared with wild-type RARS cases.11 SF3B1 mutations
are generally more prevalent in low-risk MDS and have been
shown to be independent predictors of favorable clinical outcome
in MDS in most studies.8,11 The clinical consequences of SF3B1
mutation in MDS are clear, but the functional consequences of
these mutations in human cells remain poorly understood. Altered
RNA splicing has been suggested as the mechanism underlying
the observed phenotypic changes concomitant to splicing factor
gene mutations, including SF3B1; 3,12,13 however, the target genes
in the HSC of MDS cases with SF3B1 mutations are yet to be
deﬁned.
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SF3B1 mutations in MDS are primarily heterozygous point
mutations. The presence of hotspots and the absence of nonsense
or frameshift mutations in SF3B1 in MDS patients suggest that
SF3B1 mutations are likely to be gain/change-of-function (neo-
morphic) mutations. A heterozygous Sf3b1+/− knockout mouse
model has been shown to develop ring sideroblasts, suggesting
that haploinsufﬁciency of SF3B1 may lead to their formation.11
Recent similar studies have not made this observation,
however.14,15 Thus, it is yet to be determined whether SF3B1
mutations found in MDS are loss-of-function mutations or gain/
change-of-function mutations. In this study, we thus evaluated the
effects of SF3B1 knockdown on cell growth, gene expression and
splicing in a range of myeloid cell lines and performed RNA
sequencing (RNA-Seq) on the CD34+ cells of MDS patients
harboring SF3B1 mutations.
MATERIALS AND METHODS
Myeloid cell lines culture
K562, HEL, TF1 and SKM1 cells were cultured in Roswell Park Memorial
Institute medium 1640 (Sigma-Aldrich, Gillingham, UK) containing 10%
fetal bovine serum, at 37 °C and 5% CO2. TF1 and SKM1 cultures were
supplemented with 2 and 1 ng/ml of granulocyte-macrophage colony-
stimulating factor, respectively.
SF3B1 knockdown
Three non-overlapping small interfering RNAs (siRNAs) targeting SF3B1 and
two different scramble sequences with guanine–cytosine content similar
to the siRNA sequences (Stealth Select RNAi, Invitrogen) were used to
knock down SF3B1 in myeloid cell lines. For each transfection, 30 pmol of
siRNA and 2× 106 cells were electroporated in an Amaxa Nucleofector I,
using the Amaxa cell optimization kit V (Amaxa, Gaithersburg, MD, USA).
Evaluation of green ﬂuorescent protein-positive cells obtained using the
pmaxGFP ﬂuorescent expression plasmid conﬁrmed480% of successfully
transfected cells after 24 h. Readout data are reported as mean± s.e.m.
Statistical analysis was performed using Student’s t-test.
Cell growth assay
Live and dead cells were assessed by trypan blue viability testing and
counted using a hemocytometer.
Cell cycle analysis
Cells were ﬁxed with ice cold methanol, incubated with 40 μg/ml propidium
iodide and 10 μg/ml RNaseA, as previously described.16 Data were acquired
on a BD LSRII ﬂow cytometer (BD Bioscience; Franklin Lakes, NJ, USA) and
analyzed using FLOWJO software 7.6.4 (FlowJo, Ashland, OR, USA).
Erythroid differentiation
To induce erythroid differentiation, K562, TF1 and HEL cells were cultured
with hemin 50 μM for 72 h. Erythroid differentiation was studied by
analyzing the expression level of γ-globin (HBG1) using quantitative real-
time PCR (qRT-PCR) as described previously.17 Expression of the erythroid
markers CD36, CD71 and CD235a was evaluated by ﬂow cytometry as
described previously.16
Quantitative real-time PCR
Total RNA was reverse transcribed using Retroscript kit (Ambion, Life
Technologies, Paisley, UK). The expression levels of SF3B1, ABCB7, FTMT, HBG1,
KLF1 and B2M were determined using Assays-on-Demand (Applied Biosystems,
Foster City, CA, USA). B2M expression levels were used to normalize for
differences in input complementary DNA (cDNA). Triplicate samples were run
on a LightCycler 480 Real-time PCR system (Roche Diagnostics, Lewes, UK) and
expression ratios were calculated using the ddCT method.18
Gene expression proﬁling
Total RNA (100 ng for each sample) was ampliﬁed and labeled with the 3′
IVT Express Kit (Affymetrix, Santa Clara, CA, USA), and hybridized to
Affymetrix Human Genome U133 Plus 2.0 GeneChips, as described
previously.19,20 CEL ﬁles were pre-processed using Robust Multi-chip
Average and data analysis was performed using GeneSpring 7.3.1 (Agilent,
Santa Clara, CA, USA). Pathway analysis was performed using Ingenuity
Pathway Analysis (IPA) 7.5 (Qiagen, Manchester, UK), as previously
described.19 Analysis of gene set up- or downregulation was performed
using Gene Set Enrichment Analysis,21 as previously described (false
discovery rateo0.1).2
Splicing analysis using human genome exon-junction microarray
Total RNA was DNAse treated (Invitrogen), puriﬁed (Agencourt RNA Clean XP)
and ampliﬁed (100 ng) using Ambion WT Expression Kit (Affymetrix). The
cDNA was subsequently fragmented and labeled using WT terminal labeling
kit (Affymetrix). Samples were hybridized onto Affymetrix Human genome
exon-junction arrays, which on average contain 119 unique probes per gene
spanning every exon and known exon–exon junction. CEL ﬁles were analyzed
using GenoSplice technology (www.genosplice.com).22,23 Data were normal-
ized using quantile normalization. Analysis at the exon level was performed
taking into account only exon probes. Analysis at the splicing variant level was
performed by taking into account exon–exon junction probes using the FAST
DB splicing patterns annotation (release fastdb_2012_2). Unpaired Student’s
t-test was used to determine exon and splicing pattern variation between cells
with SF3B1 knockdown and scramble controls. Genes were considered
signiﬁcantly deregulated when fold change was ⩾1.5 and P-value o0.05.
Gene Ontology, KEGG and REACTOME analyses of differentially regulated
genes were performed using DAVID.24
Splicing analysis using qRT-PCR and Sanger sequencing
Splicing analysis of TP53 was performed using Sanger sequencing of gel-
extracted individual bands from PCR-ampliﬁed cDNA. Primers and PCR
conditions are listed in Supplementary Table S1.
Splicing analysis of cyclins CCNA2 and STK6 was performed using a qRT-
PCR on cDNA, using primers speciﬁc for splice junctions corresponding to
exon inclusion or skipping.25 Primers are listed in Supplementary Table S2.
TBP expression levels were used to normalize for differences in input cDNA.
RNA sequencing
Bone marrow samples were obtained from MDS patients and healthy
controls and CD34+ cells isolated using MACS magnetic cell separation
columns (Miltenyi Biotec, Germany), as described previously.19,20 RNA
extracted from bone marrow CD34+ cells obtained from 12 MDS patients
and 5 healthy controls was used for deep RNA-Seq. Eight of the 12 MDS
cases (four RARS and four RCMD-RS) had SF3B1 gene mutation, whereas
four cases (all RCMD) had no known mutations in splicing factor genes
(SF3B1, SRSF2, U2AF1 or ZRSR2) (Supplementary Table S3), as determined
by targeted next-generation sequencing data from a previous study.7
Total RNA was DNase treated (Invitrogen), puriﬁed using XP beads
(Beckman Coulter, High Wycombe, UK) and processed (100 ng) using
NEBNext Ultra directional mRNA Library prep (NEB, Hitchin, UK) as per the
manufacturer’s protocol for Illumina with two alterations: custom indexes
were designed in house and an additional puriﬁcation step was performed
using XP beads (Beckman Coulter) rather than size selection. Samples were
run on HiSeq2000 Illumina sequencing machine (Illumina, San Diego, CA,
USA). Sequencing reads were mapped to the human genome using
TopHat,26 which can handle reads spanning exon–exon boundaries. Data
analysis was performed using edgeR27 to evaluate the whole transcript
expression (false discovery rateo0.05) and with DEXSeq28 to evaluate
differential exon usage (false discovery rateo0.05). At the expression level,
only genes with at least 10 reads in four or more samples were included in
the analysis; at the exon level, exons with fewer than 10 reads were
excluded. Gender was included as an additional factor in the DEXSeq
model testing for differential exon usage. Selected differentially expressed
exons were validated using qRT-PCR (Supplemetary Figure S1,
Supplementary Information). Integrative Genomics Viewer (IGV) v2.3
(http://www.broadinstitute.org/igv/) was used for visualization of the
sequence reads. Pathway analysis was performed using IPA and Gene
Set Enrichment Analysis, as described above. The data discussed in this
publication have been deposited in NCBI's Gene Expression Omnibus and
are accessible through GEO Series accession number GSE63569.
RESULTS
SF3B1 knockdown inhibits cell growth, induces cell cycle arrest
and impairs erythroid differentiation
SF3B1 was knocked down using siRNA technology in four myeloid
cell lines (TF1, K562, HEL and SKM1) that we found to be wild type
Disruption of SF3B1 in myelodysplastic syndromes
H Dolatshad et al
1093
© 2015 Macmillan Publishers Limited Leukemia (2015) 1092 – 1103
for SF3B1 (Supplementary Information), resulting in a signiﬁcant
decrease in expression ranging between 50 and 60% (Figure 1a).
Cell growth was inhibited in all four cell lines with SF3B1
knockdown in comparison with the scramble control (Figure 1b).
Cell cycle arrest in different phases was detected in different
myeloid cell lines with SF3B1 knockdown (Figure 1c). K562 cells
showed a signiﬁcant G2M cell cycle arrest with a concomitant
reduction in the percentage of cells in the G1 and S phase.
TF1 cells showed a signiﬁcant decrease in the percentage of cells
in the S phase. HEL cells showed a signiﬁcant decrease in the
percentage of cells in the G1 phase and a signiﬁcant increase in
the sub-G1 cell population, indicating increased apoptosis.
Similarly, SKM1 cells showed a signiﬁcant decrease in the
percentage of cells in S and G2M phase with a concomitant
increase in the percentage of cells in the sub-G1 and G1 phase,
indicating cell cycle arrest in the G1 phase and an increase in
apoptosis (Figure 1c).
Three cell lines (TF1, K562 and HEL) with SF3B1 knockdown
were cultured with hemin to induce erythroid differentiation.
We assessed the expression of the erythroid differentiation
markers HBG1 and KLF1 using qRT-PCR. A signiﬁcant reduction
in the expression of HBG1 and KLF1 was observed in TF1 and
K562 cell lines with SF3B1 knockdown (Figure 1d). In addition,
we observed a reduction in the percentage of CD36+CD71+
and CD71+CD235a+ erythroid populations (signiﬁcant for the
CD36+CD71+ population) in K562 cells with SF3B1 knockdown
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Figure 1. Effects of SF3B1 knockdown in myeloid cell lines. Each cell line transfected with siRNA targeting SF3B1 was compared with the
corresponding cell line transfected with the scramble control. (a) SF3B1 mRNA expression measured 3 days after knockdown. (b) Growth
curves of cells with SF3B1 knockdown, compared with cells transfected with the scramble control, as assessed by trypan blue exclusion. (c) Cell
cycle analysis of cell lines following SF3B1 knockdown. (d) Erythroid differentiation in myeloid cell lines with SF3B1 knockdown treated with
50 μM hemin, as measured by HBG1 and KLF1 expressions relative to the scramble control. (e) Percentage of CD36+CD71+ and CD71+CD235a+
populations in K562 cells with SF3B1 knockdown compared with the scramble control. Results in subpanels a–d were obtained from scramble
n= 2 and SF3B1 siRNA as follows: a, n= 3; b, n= 3; c, n= 3 for SKM1 and TF1, n= 6 for HEL and n= 9 for K562; d, n= 3 for TF1 and HEL, n= 6 for
K562. Results in subpanel e were obtained from scramble n= 4 and SF3B1 siRNA n= 4. *Po0.05.
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compared with the scramble control (Figure 1e), suggesting
that normal SF3B1 function is required for erythroid
differentiation.17
RARS is characterized by FTMT accumulation and low expression
levels of the iron transporter ABCB7.17,29 We have previously
shown that SF3B1 knockdown leads to decreased ABCB7 expres-
sion and increased FTMT expression in K562 cells.17 In this study,
we have extended these observations to the other three myeloid
cell lines investigated (Figure 2a). In addition, restoration of
SF3B1 expression to normal levels after 10 days of culture was
followed by restoration of ABCB7 expression levels to normal
(Supplementary Figure S2).
Taken together, these data show that SF3B1 knockdown results
in inhibition of cell growth, induction of cell cycle arrest and
impairment of erythroid differentiation in myeloid cell lines.
SF3B1 knockdown alters gene expression
To evaluate the effects of SF3B1 knockdown on global gene
expression, gene expression proﬁling was performed in the four
myeloid cell lines. For each cell line, we compared the expression
proﬁles of cells treated with two different siRNAs targeting SF3B1
with those of cells treated with a scramble control, 48 h post
transfection.
We identiﬁed many genes that were up- or downregulated
by 42-fold in each cell line treated with SF3B1 siRNAs
(Supplementary Figure S3A and S3B). Four genes were upregu-
lated (TFDP1, LOC100505759, MKRN1 and WRNIP1) and ﬁve genes
were downregulated (ZC3H7A, CREBZF, SGK494, WSB1 and two
probesets for SF3B1) in all four cell lines with SF3B1 knockdown.
Pathway analysis was performed on the up- and downregulated
genes in each cell line with SF3B1 knockdown using IPA.
Signiﬁcant deregulation of pathways related to cell cycle
regulation was observed in all cell lines and of mTOR signaling
and AMPK signaling pathways in three cell lines (Table 1). We
performed Gene Set Enrichment Analysis to identify pathways and
processes showing coordinated up- or downregulation. Upregu-
lated gene sets include p53 signaling in K562 and SKM1 cells, and
several gene sets associated with regulation of transcription,
spliceosome and splicing in K562 cells (Supplementary Table S4).
Downregulated gene sets associated with the mitochondrial
function were found in K562 and TF1 cells, and with cell cycle
regulation in SKM1 and HEL cells (Supplementary Table S4). These
data show that SF3B1 knockdown in the cell lines studied results in
deregulation of many genes and pathways including cell cycle
and RNA processing.
SF3B1 knockdown impact on splicing
The genome-wide effects of SF3B1 knockdown on splicing were
investigated in two myeloid cell lines (K562 and TF1) using human
genome exon-junction arrays. The splicing proﬁle of cells with
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Figure 2. Effects of SF3B1 knockdown on gene expression and splicing. (a) ABCB7 and FTMT expression levels in TF1, K562, HEL and SKM1 cells
with SF3B1 knockdown, as measured by qRT-PCR 48 h post transfection. Each cell line transfected with siRNA targeting SF3B1 was compared
with the corresponding cell line transfected with the scramble control. (b) Reverse transcription-PCR of TP53 exons 5–7 showing aberrant
splicing in K562 cells with SF3B1 knockdown (siRNA) compared with scramble (SCR). (c, d). qRT-PCR analysis using primers that monitor
general gene expression (GE) in a constitutive exon (Ex4 of CCNA2 and Ex3 of STK6) or primers speciﬁc for splice junctions corresponding to
exon inclusion or skipping in the cyclin A2 (CCNA2) and Aurora Kinase A (STK6) genes in K562 cells. Cells with SF3B1 knockdown (siRNA) show
alternative splicing events. Results in subpanel a were obtained from scramble n= 3 and SF3B1 siRNA n= 4. Results in subpanel c–d were
obtained from scramble n= 2 and SF3B1 siRNA n= 3. *Po0.05.
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SF3B1 knockdown (using two different siRNA per cell line) was
compared with that of cells transfected with the scramble control.
We observed 2027 differentially expressed exons from 1419
genes, and 507 signiﬁcant differentially regulated splicing variants
(including exon skipping, intron retention and alternative splice
sites) of 384 genes in cells with SF3B1 knockdown. For example,
we observed differential exon usage of CDC7 and SRSF11 in the
data from both the cell lines, and of TP53 in TF1 cells. We found a
signiﬁcant overrepresentation of 3′ acceptor splice sites affected
by alternative splicing events compared with 5′ donor splice sites
(5:1 ratio, P= 0.0027, χ2 test with Yates' correction), consistent with
the known role of SF3B1 in the recognition of 3′ splice sites. Gene
ontology analysis was performed using DAVID (http://david.abcc.
ncifcrf.gov/), and many themes showed signiﬁcant enrichment of
genes affected at the level of exon usage and splice variants
(Table 2). Cell cycle and RNA degradation were found to be
consistently deregulated at both levels (Table 2). We investigated
TP53 differential exon usage by PCR ampliﬁcation and Sanger
sequencing of gel-extracted bands. We observed exon skipping
that was present in the SF3B1 knockdown cells only (Figure 2b).
We also investigated whether two cell cycle genes (CCNA2 and
STK6) previously shown to be aberrantly spliced in HeLa cells with
Table 1. List of signiﬁcant deregulated pathways in cell lines obtained using IPA
TF1 SKM1 K562 HEL
Selenoamino acid metabolism Estrogen-mediated S-phase entry AMPK signaling Estrogen-mediated S-phase entry
Mitochondrial dysfunction Pentose phosphate pathway HMGB1 signaling Cyclins and cell cycle regulation
AMPK signaling Cell cycle: G1/S checkpoint
regulation
mTOR signaling PI3K signaling in B lymphocytes
Regulation of eIF4 and p70S6K
signaling
Small-cell lung cancer signaling Polyamine regulation in colon cancer mTOR signaling
mTOR signaling Lysine biosynthesis Cell cycle regulation by BTG family
proteins
Breast cancer regulation by
stathmin1
Role of NANOG in mammalian
embryonic stem cell pluripotency
Actin cytoskeleton signaling ILK signaling Purine metabolism
Cyclins and cell cycle regulation Chronic myeloid leukemia
signaling
Cyclins and cell cycle regulation Glioma signaling
Polyamine regulation in colon
cancer
Glioma signaling Ceramide signaling Aldosterone signaling in
epithelial cells
Assembly of RNA polymerase II
complex
Assembly of RNA polymerase III
complex
ErbB signaling fMLP signaling in neutrophils
Signaling by Rho family GTPases TNFR1 signaling Cell cycle: G1/S checkpoint
regulation
Glucocorticoid receptor signaling Non-small cell lung cancer
signaling
Glycine, serine and threonine
metabolism
Growth hormone signaling
Role of CHK proteins in cell cycle
checkpoint control
Small-cell lung cancer signaling
VDR/RXR activation Protein ubiquitination pathway
Lysine degradation Nitric oxide signaling in the
cardiovascular system
Tight junction signaling AMPK signaling
Ubiquinone biosynthesis Glioblastoma multiforme
signaling
Mitotic roles of polo-like kinase
Wnt/β-catenin signaling
PI3K/AKT signaling
Renal cell carcinoma signaling
Regulation of eIF4 and p70S6K
signaling
TNFR2 signaling
Fructose and mannose metabolism
Telomerase signaling
Gene expression proﬁling was performed in all four cell lines with SF3B1 knockdown, and genes showing 42-fold change were used for the analysis.
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Table 2. Pathway analysis using human genome exon-junction array data at two different levels: differential exon usage and different splicing
variant
Pathways affected by diferential exon usage Pathways affected by differential splice variant usage
Pathway description P-value Pathway description P-value
KEGG pathway
Ubiquitin-mediated proteolysis 1.82E− 05 RNA degradation 7.85E− 05
Cell cycle 1.02E− 04 Oocyte meiosis 4.23E− 03
Spliceosome 3.22E− 04 Cell cycle 8.45E− 03
Oocyte meiosis 3.88E− 04 Progesterone-mediated oocyte maturation 2.17E− 02
Phosphatidylinositol signaling system 8.92E− 04 Aminoacyl-tRNA biosynthesis 4.04E− 02
Inositol phosphate metabolism 1.68E− 03
RNA degradation 2.30E− 02
Ribosome 2.58E− 02
One carbon pool by folate 2.65E− 02
Aminoacyl-tRNA biosynthesis 2.91E− 02
Selenoamino acid metabolism 3.93E− 02
Insulin signaling pathway 4.03E− 02
REACTOME pathway
Cell cycle, mitotic 1.19E− 09 Cell cycle, mitotic 4.43E− 05
Gene expression 1.47E− 04 Gene expression 1.29E− 02
DNA repair 1.75E− 03 Cell cycle checkpoints 2.20E− 02
APC-Cdc20-mediated degradation of Nek2A 9.97E− 03
Cell cycle checkpoints 1.13E− 02
Transcription 1.22E− 02
Signaling by Wnt 2.91E− 02
Signaling by NGF 3.63E− 02
Cdc20:Phospho-APC/C-mediated degradation of cyclin A 4.70E− 02
Table 3. Pathway analysis (IPA) of the signiﬁcant differentially expressed genes between SF3B1 mutant and wild type obtained using edgeR
Ingenuity canonical pathways P-value Ratio Molecules
Lymphotoxin β receptor signaling 0.00074131 9.68E− 02 NFKBID, BCL2L1, CASP3, RELB, CXCL1 and TRAF1
Agranulocyte adhesion and diapedesis 0.001071519 5.73E− 02 CXCL3, PODXL2, CCL4,CLDN19, CXCL14, CXCL1, CCL3L1/
CCL3L3, MMP2, CXCL2, MYH7B and
CCL4L1/CCL4L2
Heme biosynthesis II 0.001096478 1.67E− 01 FECH, ALAS2, CPOX and HMBS
Hepatic ﬁbrosis/hepatic stellate cell activation 0.00162181 5.81E− 02 CXCL3, LEPR, IL6R, MMP2, LBP, IL6, MYH7B, AGTR1 and
PGF
Communication between innate and adaptive immune cells 0.001995262 6.25E− 02 CCL4, TLR7, CCL3L1/CCL3L3, CD83, IGHG1, IGHA1 and
IL6
Colorectal cancer metastasis signaling 0.003467369 4.48E− 02 BCL2L1, ADCY9, CDH1, JUN, CASP3, PTGER3, DIRAS3,
IL6R, TLR7, MMP2, IL6 and PGF
IL-17A signaling in ﬁbroblasts 0.004570882 1E− 01 NFKBID, JUN, IL6 and NFKBIZ
Toll-like receptor signaling 0.004570882 7.81E− 02 JUN, TLR7, TNFAIP3, LBP and TRAF1
Differential regulation of cytokine production in macrophages
and T-helper cells by IL-17A and IL-17F
0.004786301 1.67E− 01 CCL4, CXCL1 and IL6
Granulocyte adhesion and diapedesis 0.007762471 4.95E− 02 CXCL3, CCL4, CLDN19, CXCL14, CXCL1, CCL3L1/CCL3L3,
MMP2, CXCL2 and CCL4L1/CCL4L2
Airway pathology in chronic obstructive pulmonary disease 0.009772372 1.82E− 01 CXCL3 and MMP2
TNFR2 signaling 0.016595869 8.82E− 02 JUN, TNFAIP3 and TRAF1
Heme bosynthesis from uroporphyrinogen-III I 0.018620871 1.82E− 01 FECH and CPOX
Aryl hydrocarbon receptor signaling 0.024547089 4.09E− 02 TGM2, CCNE1, GSTM2, ALDH1A1, JUN, NQO2 and IL6
NRF2-mediated oxidative stress response 0.025118864 4.1E− 02 GSR, JUN, GSTM2, NQO2, DNAJC6, JUND, FOSL1
and ABCC4
Role of IL-17A in psoriasis 0.025703958 1.43E− 01 CXCL3 and CXCL1
Gα12/13 signaling 0.028840315 4.72E− 02 BTK, CDH7, CDH1, JUN, MEF2D and CDH11
Tetrapyrrole biosynthesis II 0.029512092 1.43E− 01 ALAS2 and HMBS
CDK5 signaling 0.033884416 5.15E− 02 FOSB, PPP1CC, ADCY9, PPM1J and EGR1
CD40 signaling 0.033884416 5.63E− 02 JUN, TNFAIP3, MAPKAPK2 and TRAF1
Mitotic roles of polo-like kinase 0.041686938 5.41E− 02 PLK3, PPM1J, ANAPC13 and CCNB1
Adenine and adenosine salvage III 0.042657952 1.18E− 01 PNP and ADAT3
Tryptophan degradation to 2-amino-3-carboxymuconate
semialdehyde
0.046773514 1.11E− 01 HAAO and KYNU
T-helper cell differentiation 0.047863009 5.56E− 02 STAT4, IL6R, IL6 and RORC
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SF3B1 knockdown,25 were also aberrantly spliced in K562 cells
with SF3B1 knockdown in our study. Consistent with the ﬁnding in
HeLa cells, we observed aberrant splicing of these genes using a
qRT-PCR strategy as described previously (Figure 2c and d).25
RNA-Seq in HSPC from MDS patients with SF3B1 mutations
To gain insight into the spectrum of genes that are deregulated or
aberrantly spliced in association with SF3B1 mutation in the
hematopoietic stem and progenitor cells (HSPC) of MDS patients,
we used deep RNA-Seq to compare the transcriptome of bone
marrow CD34+ cells from eight MDS patients with SF3B1 mutation
(SF3B1 mutants), four MDS patients with no known splicing
mutation (wild type) and ﬁve healthy controls (control)
(Supplementary Table S3). Using IGV, we evaluated the expression
of the SF3B1 alleles in SF3B1 mutant cases and observed a range of
45–52% of mutant allele frequency, indicating that both wild-type
and mutant alleles were equally expressed (Supplementary Table
S3, Supplementary Figure S4).
We used edgeR to perform differential gene expression analysis
of SF3B1 mutants versus wild type and control. At the whole
transcript level, we observed a total of 526 genes (253
upregulated and 273 downregulated) signiﬁcantly differentially
expressed in SF3B1 mutants in comparison with wild type
(Supplementary Table S5). In the comparison of SF3B1 mutants
with control, we found 1823 signiﬁcantly differentially expressed
genes (646 upregulated and 1177 downregulated)
(Supplementary Table S6). Genes linked to the pathogenesis of
RARS and RCMD-RS, such as ALAS2 and ABCB7, were deregulated
(ALAS2 upregulated and ABCB7 downregulated) in both compar-
isons of SF3B1 mutant with wild type and control. We also
observed upregulation of the mitochondrial genes SLC25A37
when comparing SF3B1 mutant with control and GLRX5 in both
comparisons of SF3B1 mutant with wild type and control.
We performed an analysis using 121 genes either known to be
expressed in erythroid cells30 or described as erythroid transcrip-
tion factors in the literature. We found 42 differentially expressed
genes (37 upregulated and 5 downregulated) when comparing
SF3B1 mutant with control. These included heme biosynthetic
enzymes (for example, ALAS2, ALAD, FECH and UROD), globin
genes (for example, HBQ1, HBA2, HBB and HBA1) and transcription
factors (for example, GATA1, GATA2 and KLF1). In the comparison
of SF3B1 mutant with wild type, we found a total of 32
differentially expressed genes (31 upregulated and 1 down-
regulated) of which 28 were overlapping with the differentially
Table 4. Top ranking genes showing differential exon usage between SF3B1 mutant and control, obtained from RNA sequencing data analysis using
DEXSeq
Gene ID Exon ID Gene name Chromosome Strand P-value Padj FC
ENSG00000125354 E011 SEPT6 X − 1 1.67E− 78 5.19E− 73 0.822522658
ENSG00000111843 E006 TMEM14C 6 1 2.80E− 51 4.36E− 46 0.803897136
ENSG00000131669 E006 NINJ1 9 − 1 1.09E− 33 1.13E− 28 0.835812796
ENSG00000088986 E014 DYNLL1 12 1 1.21E− 28 9.43E− 24 0.913566493
ENSG00000223865 E018 HLA-DPB1 6 1 3.05E− 27 1.90E− 22 1.357267219
ENSG00000101019 E025 UQCC1 20 − 1 1.71E− 26 8.88E− 22 0.889537433
ENSG00000132199 E025 ENOSF1 18 − 1 2.57E− 24 1.14E− 19 0.905515696
ENSG00000125991 E049 ERGIC3 20 1 4.11E− 23 1.42E− 18 0.870728412
ENSG00000101019 E024 UQCC1 20 − 1 2.01E− 22 6.25E− 18 0.878172451
ENSG00000118495 E010 PLAGL1 6 − 1 2.78E− 22 7.85E− 18 1.753766932
ENSG00000266086 E005 RP11-159D12.5 17 − 1 1.43E− 18 3.43E− 14 1.051487592
ENSG00000119777 E023 TMEM214 2 1 1.35E− 18 3.43E− 14 0.724952987
ENSG00000130066 E011 SAT1 X 1 2.63E− 17 5.83E− 13 1.224469811
ENSG00000101019 E029 UQCC1 20 − 1 3.49E− 17 7.24E− 13 0.987866168
ENSG00000141425 E015 RPRD1A 18 − 1 2.14E− 16 3.91E− 12 1.151614234
ENSG00000268400 E058 CTD-3214H19.4 19 1 2.08E− 16 3.91E− 12 0.720165623
ENSG00000127586 E055 CHTF18 16 1 2.45E− 16 4.24E− 12 0.83461565
ENSG00000130066 E015 SAT1 X 1 4.80E− 16 7.86E− 12 1.112053709
ENSG00000160789 E072 LMNA 1 1 1.00E− 15 1.56E− 11 0.74131183
ENSG00000130066 E010 SAT1 X 1 1.22E− 15 1.81E− 11 1.175909464
ENSG00000119777 E024 TMEM214 2 1 6.13E− 15 8.66E− 11 0.769414939
ENSG00000266086 E004 RP11-159D12.5 17 − 1 1.51E− 14 2.04E− 10 1.073999383
ENSG00000168675 E009 LDLRAD4 18 1 4.10E− 14 5.10E− 10 0.882283199
ENSG00000160789 E071 LMNA 1 1 6.34E− 14 7.58E− 10 0.907377148
ENSG00000214021 E019 TTLL3 3 1 1.13E− 13 1.30E− 09 1.027729333
ENSG00000196576 E041 PLXNB2 22 − 1 1.59E− 13 1.77E− 09 0.53703246
ENSG00000166508 E021 MCM7 7 − 1 2.21E− 13 2.37E− 09 1.034956343
ENSG00000114770 E040 ABCC5 3 − 1 2.75E− 13 2.79E− 09 1.290748901
ENSG00000196365 E028 LONP1 19 − 1 2.78E− 13 2.79E− 09 0.876937237
ENSG00000130066 E002 SAT1 X 1 3.59E− 13 3.49E− 09 0.967812734
ENSG00000102119 E017 EMD X 1 3.76E− 13 3.55E− 09 1.050545479
ENSG00000130066 E014 SAT1 X 1 5.55E− 13 5.08E− 09 1.168469304
ENSG00000266086 E006 RP11-159D12.5 17 − 1 5.72E− 13 5.08E− 09 1.073091463
ENSG00000055609 E005 KMT2C 7 − 1 6.09E− 13 5.26E− 09 1.089688525
ENSG00000228315 E065 GUSBP11 22 − 1 6.70E− 13 5.63E− 09 1.125912723
ENSG00000156860 E023 FBRS 16 1 7.27E− 13 5.95E− 09 1.10075677
ENSG00000268400 E071 CTD-3214H19.4 19 1 8.37E− 13 6.67E− 09 1.139015436
ENSG00000214021 E065 TTLL3 3 1 1.15E− 12 8.34E− 09 1.269221488
ENSG00000122566 E004 HNRNPA2B1 7 − 1 1.10E− 12 8.34E− 09 1.160615984
ENSG00000101557 E035 USP14 18 1 1.13E− 12 8.34E− 09 1.043528763
Genes are ranked by adjusted P-value (Padj).
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expressed genes found when comparing SF3B1 mutant with
control.
We then performed pathway analysis on the signiﬁcantly
differentially expressed genes using IPA. Many pathways, includ-
ing heme biosynthesis, mitotic roles of polo-like kinase and TNFR2
signaling, were signiﬁcantly deregulated in the comparison of
SF3B1 mutant with wild type (Table 3). When comparing SF3B1
mutant with control, signiﬁcantly deregulated pathways included
apoptosis signaling, p53 signaling, cell cycle regulation and heme
degradation (Supplementary Table S7). We next performed Gene
Set Enrichment Analysisand many gene sets showing signiﬁcant
enrichment were identiﬁed in SF3B1 mutant versus wild type and
control. Upregulated gene sets included several that were related
to mitochondrial function, cell cycle checkpoints and mRNA
splicing. In the comparison of SF3B1 mutant with control cases,
downregulated gene sets included several that were related to cell
differentiation and apoptosis (Supplementary Table S8). Many of
these deregulated pathways and gene sets are relevant to the
known pathophysiology of MDS and in particular of RARS and
RCMD-RS.
DEXSeq was used to perform differential exon usage analysis of
the RNAseq data to evaluate aberrantly spliced genes. At the exon
level, we observed a total of 3506 exons (corresponding to 1924
genes) signiﬁcantly differentially expressed in SF3B1 mutant
compared with control (Table 4, Figure 3, Supplementary Table S9).
Differential exon usage was observed in at least one exon of
genes known to be involved in MDS pathophysiology (TP53 and
EZH1), erythroid genes (ALAD, UROD and EPB42) and genes
associated with cell cycle (AURKB and CRNDE) and RNA processing
(RBM5, RBM25, PRPF40A and HNRNPD). When comparing SF3B1
mutant with wild type cases, we found 3097 signiﬁcantly
differentially expressed exons (corresponding to 2022 genes)
(Table 5, Figure 4, Supplementary Table S10). We found differential
exon usage in at least one exon of genes involved in MDS
pathophysiology (CBL, ASXL1 and DNMT3A), mitochondrial
function (ALAS2, NDUFAF6), erythroid differentiation (NFE2L2, PPOX
and HMBS) and mRNA processing (HNRNPD, U2AF2 and
PRPF8). Interestingly, UQCC1, a gene involved in mitochondrial
biogenesis31 and showing abnormal splicing in SF3B1 mutant
cases in uveal melanoma,32 showed differential exon usage and
upregulation in SF3B1 mutant cases compared with wild type and
control in our study.
To identify pathways affected by differential exon usage, we
performed pathway analysis on the genes showing signiﬁcantly
differentially expressed exons using IPA. In the comparison of
SF3B1 mutant with wild type and control, we observed many
pathways to be affected, including cell cycle, heme biosynthesis,
DNA damage response, mitochondrial and haematopoietic
progenitor cells pathway (Supplementary Table S11 and S12).
Using DAVID functional annotation tool, we observed signiﬁcant
enrichment of biological themes including alternative splicing,
RNA binding, mitochondrion, spliceosome and cell cycle.
Recently, a role for SF3B1 in the maintenance of genomic
stability has also been reported where it functions in a DNA
damage-induced mRNA splicing complex with BRCA1 and
BCLAF1.33 Given that deregulation of the DNA damage response
pathway was highlighted by the IPA pathway analysis, we
performed an analysis using genes regulated by the BRCA1–
BCLAF1–SF3B1 complex. Several genes regulated by this complex
showed differential exon usage in SF3B1 mutant compared with
control (including NUMA1, RB1, CHUK and ABL1) and compared
with wild type (NUMA1, PIAS1, SMAD4, BIRC2 and PTK2)
(Supplementary Table S13). The overrepresentation of genes
regulated by the BRCA1–BCLAF1–SF3B1 complex was signiﬁcant
in SF3B1 mutant compared with control (Po0.001) and compared
with wild type (P= 0.0498, hypergeometric test). We also found
many genes to be affected at the transcript level, including BIRC3,
BCL2A1, GYPB, HBB and HBBP1 when comparing SF3B1 mutant
with wild type and control (Supplementary Table S13).
Figure 3. Examples of genes showing signiﬁcant differential exon usage between MDS patients with SF3B1 mutation in comparison with
control, obtained from RNA-Seq data analysis using DEXSeq. The graphs show some of the top ranking genes with signiﬁcant differential exon
usage. The exons highlighted in purple represent the signiﬁcant differential exon usage.
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DISCUSSION
The identiﬁcation of frequent somatic mutations of SF3B1 in MDS
patients with ring sideroblasts suggests a direct correlation
between the presence of mutations and this particular
phenotype.2,11,13 However, the mechanism by which SF3B1
mutation leads to MDS with ring sideroblasts remains to be
elucidated.
To illuminate the role of SF3B1 mutation in MDS pathophysiol-
ogy, we have determined the effects of SF3B1 disruption on cell
growth and gene expression in human hematological cells. First,
we investigated the effects of SF3B1 knockdown on cell function
and gene expression in myeloid cell lines. Second, we used RNA-
Seq to study the global gene expression changes and splicing
abnormalities associated with the presence of SF3B1 mutations in
the HSPC of MDS patients.
We have shown that SF3B1 knockdown in four myeloid cell lines
resulted in inhibition of cell growth and disruption of the cell
cycle. It has recently been reported that Sf3b1+/− mice showed
reduced numbers of HSC and compromised reconstitution
capacity in lethally irradiated mice.14,15 Thus, reduced expression
of SF3B1 appears to result in impaired cell growth in hemato-
poietic cells. Similar observations have been made following
reduced expression of other splicing factor genes, including
U2AF1.3,4,34
We used two different microarray platforms to identify genes
deregulated at the transcriptional and exon level by SF3B1
knockdown in myeloid cell lines. Gene expression proﬁling
identiﬁed many deregulated genes, with four genes consistently
upregulated, including TFDP1, and ﬁve genes downregulated,
including CREBZF, in all four cell lines with SF3B1 knockdown,
several of which have a role in the control of cell growth. TFDP1 is
involved in the control of transcriptional activity of G1/S cell cycle
checkpoint genes,35 and CREBZF is a potent suppressor of cell
growth, the effects of which are mediated through the tumor
suppressor p53.36 Next, we employed exon-junction arrays to
study the transcriptome in K562 and TF1 cells. We identiﬁed many
differentially expressed exons and differentially regulated splicing
variants in cells with SF3B1 knockdown. For example, we observed
differential exon usage of the CDC7 and SRSF11 genes, involved in
cell cycle regulation and splicing, respectively, and of the TP53
gene. Several pathways including cell cycle, RNA processing,
mitochondrion and apoptosis/p53 pathway were consistently
deregulated in the cell lines with SF3B1 knockdown.
In summary, our data on myeloid cell lines suggest that the
phenotype observed in cells with SF3B1 knockdown is mediated
Table 5. Top ranking genes showing differential exon usage between SF3B1 mutant and wild type, obtained from RNA sequencing data analysis
using DEXSeq
Gene ID Exon ID Gene name Chromosome Strand P-value Padj FC
ENSG00000125354 E011 SEPT6 X − 1 9.38E− 92 3.53E− 86 0.827252395
ENSG00000132199 E025 ENOSF1 18 − 1 5.10E− 33 9.59E− 28 0.911519852
ENSG00000189283 E004 FHIT 3 − 1 1.73E− 28 2.18E− 23 3.663047029
ENSG00000101019 E025 UQCC1 20 − 1 9.24E− 28 8.69E− 23 0.72317914
ENSG00000111843 E006 TMEM14C 6 1 9.84E− 26 7.40E− 21 0.91596329
ENSG00000125991 E049 ERGIC3 20 1 9.81E− 23 6.15E− 18 0.791616483
ENSG00000071082 E025 RPL31 2 1 3.50E− 21 1.88E− 16 0.717351893
ENSG00000101019 E029 UQCC1 20 − 1 2.62E− 20 1.23E− 15 0.701671242
ENSG00000211644 E016 IGLV1-51 22 1 3.99E− 20 1.67E− 15 0.441359946
ENSG00000088986 E014 DYNLL1 12 1 5.65E− 20 2.12E− 15 0.845893878
ENSG00000028310 E077 BRD9 5 − 1 3.97E− 18 1.36E− 13 0.767361674
ENSG00000127586 E055 CHTF18 16 1 2.12E− 17 6.64E− 13 0.878313474
ENSG00000101019 E007 UQCC1 20 − 1 3.20E− 17 9.25E− 13 1.47227241
ENSG00000160710 E024 ADAR 1 − 1 1.30E− 16 3.51E− 12 1.320985378
ENSG00000101019 E024 UQCC1 20 − 1 2.02E− 16 5.06E− 12 0.71746253
ENSG00000118495 E010 PLAGL1 6 − 1 4.10E− 16 9.65E− 12 2.538692764
ENSG00000255863 E017 AC073610.5 12 − 1 1.20E− 15 2.65E− 11 0.882954589
ENSG00000211644 E017 IGLV1-51 22 1 1.38E− 15 2.88E− 11 0.485819764
ENSG00000075218 E014 GTSE1 22 1 2.48E− 15 4.91E− 11 1.468605485
ENSG00000137133 E004 HINT2 9 − 1 2.09E− 14 3.93E− 10 0.839329231
ENSG00000205593 E031 DENND6B 22 − 1 5.28E− 14 9.46E− 10 4.609575952
ENSG00000101019 E013 UQCC1 20 − 1 1.05E− 13 1.74E− 09 2.895712194
ENSG00000101019 E026 UQCC1 20 − 1 1.11E− 13 1.74E− 09 0.732192837
ENSG00000101019 E028 UQCC1 20 − 1 1.10E− 13 1.74E− 09 0.698206407
ENSG00000103426 E028 CORO7-PAM16 16 − 1 1.21E− 13 1.83E− 09 0.838759667
ENSG00000205593 E030 DENND6B 22 − 1 3.43E− 13 4.97E− 09 4.61396886
ENSG00000101019 E010 UQCC1 20 − 1 4.54E− 13 6.33E− 09 1.74387423
ENSG00000111640 E017 GAPDH 12 1 8.37E− 13 1.12E− 08 1.387332969
ENSG00000100387 E034 RBX1 22 1 1.24E− 12 1.61E− 08 1.875629945
ENSG00000271270 E006 TMCC1-AS1 3 1 2.12E− 12 2.66E− 08 2.979442225
ENSG00000028310 E078 BRD9 5 − 1 3.00E− 12 3.64E− 08 0.795339192
ENSG00000101019 E027 UQCC1 20 − 1 3.26E− 12 3.84E− 08 0.703747197
ENSG00000255103 E077 KIAA0754 1 1 3.38E− 12 3.85E− 08 1.663519412
ENSG00000268400 E035 CTD-3214H19.4 19 1 3.57E− 12 3.95E− 08 1.463054031
ENSG00000205593 E032 DENND6B 22 − 1 4.28E− 12 4.60E− 08 4.764064117
ENSG00000136044 E042 APPL2 12 − 1 5.63E− 12 5.88E− 08 0.720698938
ENSG00000101019 E005 UQCC1 20 − 1 1.00E− 11 9.92E− 08 1.53637968
ENSG00000167323 E043 STIM1 11 1 9.97E− 12 9.92E− 08 0.766910234
ENSG00000101019 E016 UQCC1 20 − 1 1.35E− 11 1.28E− 07 2.2692562
ENSG00000161013 E025 MGAT4B 5 − 1 1.36E− 11 1.28E−07 1.097105348
Genes are ranked by adjusted P-value (Padj).
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by aberrant splicing and expression of target genes involved in
key biological processes.
RNA-Seq is the method of choice for a comprehensive analysis
of global gene expression and splicing. In all relevant studies
published to date, RNA-Seq has been performed on unfractio-
nated bone marrow mononuclear cells from a small number of
MDS patients with SF3B1 mutations (n⩽ 3 per study), revealing
interesting data.11,37,38 MDS arise in the HSC, and it is thus of
critical importance that the effects of SF3B1 mutation on the
transcriptome are studied in the cell of origin. In this study, we
performed RNA-Seq on puriﬁed bone marrow CD34+ cells from 12
MDS patients, eight with ring sideroblasts and SF3B1 mutation and
four without mutation in other splicing factor genes, and from ﬁve
healthy controls.
We identiﬁed many signiﬁcantly differentially expressed genes
at the transcript level and the exon level when comparing
SF3B1 mutant with wild type and control. CD34+ cells from RCMD-
RS and RARS patients display a particular expression proﬁle
of mitochondria-related genes;17,20 we observed upregulation of
ALAS2 (heme biosynthesis enzyme) and downregulation of
ABCB7 (involved in the transport of iron from the mitochondria
to the cytoplasm) in SF3B1 mutants compared with wild type
and control, in agreement with our previous reports.17,20
SLC25A37, encoding a mitochondrial iron importer, and GLRX5,
encoding another mitochondrial protein, were both signiﬁcantly
upregulated in CD34+ cells of SF3B1 mutants compared with wild
type and control. A recent study showed SLC25A37 mRNA
upregulation in SF3B1 mutant bone marrow mononuclear cells
of three MDS patients with RARS/-T.38 Evidence is thus mounting
to suggest that upregulation of the iron importer SLC25A37 and
downregulation of iron exporter ABCB7 may be linked to the
increased mitochondrial iron accumulation observed in MDS
patients with ring sideroblasts.39 Deregulation of these genes
could also be consistent with an impaired ability of mitochondrial
pathways to use iron that may result in an attempt to increase iron
availability.
Importantly, we observed many genes associated with por-
phyrin and heme biosynthesis showing differential exon usage in
SF3B1 mutant cases, indicating altered splicing. These include
ALAD and UROD when comparing SF3B1 mutant with control and
Figure 4. Examples of genes showing signiﬁcant differential exon usage in MDS patients with SF3B1 mutation in comparison with wild type,
obtained from RNA-Seq data analysis using DEXSeq. The graphs show some of the top ranking genes with signiﬁcant differential exon usage.
The exons highlighted in purple represent the signiﬁcant differential exon usage.
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ALAS2 and PPOX when comparing with wild type. We suggest that
the aberrant expression and exon usage of mitochondrial and
heme-related genes in the CD34+ cells of MDS patients with SF3B1
mutation has a role in ring sideroblast formation and abnormal
iron homeostasis observed in this patient group. Intriguingly, the
most common congenital sideroblastic anemia (X-linked side-
roblastic anemia) results from an ALAS2 mutation.40
The relative expression levels of the transcription factors GATA1
and GATA2 differed from normal in the CD34+ cells of MDS
patients with SF3B1 mutation. The dynamic and strictly regulated
change of expression from GATA2 to GATA1 during erythropoiesis
has a crucial role,41 and any alteration of this pattern may be
predicted to lead to aberrant erythropoiesis. We suggest that the
aberrant expression and splicing of erythroid-related genes
observed in the CD34+ cells of MDS patients with SF3B1 mutation
may have a role in the ineffective erythropoiesis found in these
patients.
In a previous study, RNA-Seq was used to compare the
transcriptome of bone marrow mononuclear cells of two MDS
patients with SF3B1 mutation to that of one healthy control.11 One
hundred and thirty genes showed signiﬁcant differential expres-
sion, 28 of which overlap with the genes differentially expressed
between SF3B1 mutant and control in our study of CD34+ cells.
These genes include MAP3K8 and CLEC5A, which have been
previously shown to be downregulated in MDS.19,42 Furthermore,
350 genes showed differential exon usage, and 52 of these were in
common with the genes showing differential exon usage in our
study of CD34+ cells. The overlapping genes include EZH1, ASXL1,
CBL1 and SMAD4.
The mutant forms of ASXL1, CBL and TP53 are known to have an
important role in the molecular pathogenesis of MDS, and
intriguingly all these genes were found to be alternatively spliced
in the HSPC of MDS patients harboring SF3B1 mutations.
A recent study identiﬁed a DNA damage-induced BRCA1
protein complex containing BCLAF1 and SF3B1 (BRCA1–BCLAF1–
SF3B1 complex).33 In response to DNA damage, the complex
regulates pre-mRNA splicing of genes involved in DNA damage
signaling and repair and hence affects their transcription and pre-
mRNA maturation.33 Importantly, we found many of the genes
regulated by this complex to be differentially expressed and to
show differential exon usage in our study. Genes showing
differential transcript level changes included BIRC3 and BCL2A1,
whereas NUMA1 showed differential exon usage when comparing
SF3B1 mutant with wild type and control. When comparing SF3B1
mutant with wild type, we also found differential exon usage of
the PIAS1 gene, a DNA damage response regulator.43,44 It has been
demonstrated that abrogation of members of this complex
including BRCA1 and BCLAF1 results in genomic instability,33 a
common feature of malignant cells. In MDS patients with mutant
SF3B1, the function of this complex may be impaired, with
possible downstream effects on the efﬁciency of DNA damage
repair.
Many genes involved in RNA splicing and processing were
found to show differential transcript levels, as well as differential
exon usage in our study, including HNRNPD, U2AF2, PRPF8 and
RBM25. A recent study showed RNA processing genes to be
misspliced in the bone marrow mononuclear cells of MDS/AML
patients with U2AF1 mutation.45 Intriguingly, there is limited
overlap between the genes misspliced as a result of U2AF1
mutation and the RNA processing/splicing genes deregulated/
aberrantly spliced in our SF3B1 mutant cases in both comparisons
of SF3B1 mutant with wild type and control, suggesting that this
process may be affected by different splicing mutations even if
their target genes are distinct.
A recent study showed that defects in the splicing factor gene
PRPF8 result in missplicing in myeloid malignancies and are
associated with the presence of ring sideroblasts in advanced MDS
and AML.46 Interestingly, we observed differential exon usage of
PRPF8 in SF3B1 mutant cases compared with control in our study,
indicating a link between SF3B1 and PRPF8 and the ring
sideroblast phenotype. Our ﬁnding of differential exon usage of
multiple RNA processing/splicing genes in the HSPC of cases with
SF3B1 mutation points towards an exacerbation of aberrant
splicing, with a wider number of downstream target genes
affected. Emerging evidence from our study on SF3B1 and the
study on U2AF145 thus supports the hypothesis that in MDS
patients harboring splicing factor mutations, there is widespread
disruption of the splicing machinery as a consequence of
downstream effects of the mutant protein. Loss-of-function
mutations in zebraﬁsh Prpf8 have been shown to result in
missplicing of TP53.47 We found TP53 to be aberrantly spliced in
MDS patients with SF3B1 mutation compared with wild type and
control.
Splicing factor mutations, including SF3B1, are considered to be
founder mutations and must confer a selective growth advantage
to the HSC, but how this occurs remains a mystery. We have
identiﬁed differential splicing in several genes known to have a
role in MDS pathogenesis, including TP53 and ASXL1, as well as
genes involved in DNA damage repair, in the HSPC of MDS
patients harboring SF3B1 mutations. We suggest that the aberrant
splicing of such genes may confer oncogenic properties that help
drive the malignant process. In this study, we have determined the
target genes of SF3B1 mutations in the HSPC of MDS patients with
ring sideroblasts, shedding light on the mechanisms underlying
this phenotype.
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